Kite Pharma
1601 Cloverfield Blvd., 100 South Tower
Santa Monica
CA
90404
United States
Tel: 424301-3670
28 articles with Kite Pharma
-
Kite Announces New Yescarta® Data From ZUMA-1
6/3/2019
Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment
-
Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities
4/24/2019
The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies
-
Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
12/4/2018
Ongoing Phase 1/2 Study Continues to Demonstrate High Rates of Response to a Single Infusion of KTE-X19 in a Patient Population with Limited Treatment Options
-
Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma
12/2/2018
39 Percent of Patients in Ongoing Response Two Years after a Single Infusion of Yescarta in the ZUMA-1 Study; Median Overall Survival was Not Reached
-
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.
-
Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer
10/2/2018
Agreement to develop technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.
-
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
-
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
7/23/2018
Gamida Cell today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.
-
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors
7/19/2018
Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.
-
Kite, a Gilead company based in Santa Monica, California, signed an agreement with Utrecht, Netherlands-based Gadeta BV. The companies will work on discovering and developing novel cancer immunotherapies based on gamma-delta T-cell receptors (TCRs).
-
Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
7/9/2018
Mr. Amoroso Brings Significant Expertise in Oncology to New Role
-
Since Allogene Therapeutics launched in April the company has been rapidly expanding its leadership team as it drives forward with a mission of developing allogeneic CAR-T therapies.
-
Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
6/4/2018
Kite, a Gilead Company announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
6/4/2018
Kite, a Gilead Company (Nasdaq: GILD), announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV.
-
Two months after walking away from his role as head of R&D and chief scientific officer at Gilead Sciences, Norbert Bischofberger has re-emerged at the helm of startup Kronos Bio, Inc.
-
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
5/15/2018
-- Facilities in the Netherlands and the United States Will Help Advance Manufacturing of Cell Therapies for People with Cancer --
-
In anticipation of marketing approval in Europe, Gilead Sciences has leased a 117,000 square-foot facility in The Netherlands to manufacture and deliver Yescarta, its CAR-T product, to patients across Europe.
-
Gilead—Down but Not Out?
5/11/2018
You know when an analyst starts an article with, “Gilead’s Q1 financial results were a disaster,” that it requires a closer look. -
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
-
Pfizer, based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.